Trupanion (NASDAQ:TRUP) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Trupanion (NASDAQ:TRUP) issued its earnings results on Thursday. The financial services provider reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.04, FiscalAI reports. The firm had revenue of $384.05 million for the quarter, compared to the consensus estimate of $379.76 million. Trupanion had a net margin of 1.35% and a return on equity of 5.39%. The business’s revenue was up 12.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.03) earnings per share.

Here are the key takeaways from Trupanion’s conference call:

• Adjusted operating income exceeded $40 million in Q1, up 29% YoY, and management reaffirmed a full‑year AOI target (~$180M), providing capital to fund growth initiatives.
• Subscription growth and retention were strong — subscription revenue $269.5M (+16% YoY), total subscription pets 1.106M (+5%), MARPP $85.79 (+11%), and trailing 12‑month retention 98.35%, supporting durable per‑pet economics.
• Margins improved as cost of paying veterinary invoices fell to 70.8% (from 71.8%), subscription adjusted operating margin hit a Q1 record of 14.2% (+130 bps), and combined fixed+variable spending declined to 14.9% of revenue.
• Management is expanding product choice and launching a new digital‑first product later this year; early rollouts (Canada and select U.S. states) show improved web conversion and customers largely choosing coverage levels similar to the core offering.
• Customer acquisition costs increased — average pet acquisition cost (ex‑MGA) rose to $315 from $267 last year, with $21.2M of AOI deployed to add ~64.7k pets, which could pressure near‑term returns if acquisition efficiency weakens.

Trupanion Stock Performance

Shares of TRUP traded down $1.09 during mid-day trading on Thursday, hitting $23.99. 605,551 shares of the company traded hands, compared to its average volume of 322,378. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.69 and a current ratio of 1.69. The stock has a 50-day moving average price of $26.31 and a two-hundred day moving average price of $32.95. Trupanion has a 1 year low of $23.90 and a 1 year high of $57.88. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of 53.31 and a beta of 1.66.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on TRUP. Bank of America dropped their target price on shares of Trupanion from $63.00 to $59.00 and set a “buy” rating on the stock in a research note on Tuesday, April 14th. Weiss Ratings downgraded shares of Trupanion from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, March 4th. Zacks Research downgraded shares of Trupanion from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 13th. Stifel Nicolaus dropped their target price on shares of Trupanion from $35.00 to $31.00 and set a “hold” rating on the stock in a research note on Tuesday, March 31st. Finally, Cantor Fitzgerald dropped their target price on shares of Trupanion from $42.00 to $34.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Trupanion has an average rating of “Hold” and an average target price of $45.80.

Insider Activity

In other news, COO John R. Gallagher sold 5,283 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $26.52, for a total transaction of $140,105.16. Following the completion of the transaction, the chief operating officer directly owned 32,387 shares of the company’s stock, valued at $858,903.24. The trade was a 14.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Fawwad Qureshi sold 4,645 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $25.61, for a total transaction of $118,958.45. The SEC filing for this sale provides additional information. Insiders sold 21,503 shares of company stock valued at $578,537 over the last three months. Insiders own 5.42% of the company’s stock.

Institutional Trading of Trupanion

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. EP Wealth Advisors LLC purchased a new stake in Trupanion during the fourth quarter valued at approximately $380,000. Bayesian Capital Management LP purchased a new stake in Trupanion during the second quarter valued at approximately $369,000. CIBC Bancorp USA Inc. purchased a new stake in Trupanion during the third quarter valued at approximately $367,000. Laurion Capital Management LP purchased a new stake in Trupanion during the fourth quarter valued at approximately $353,000. Finally, Nebula Research & Development LLC purchased a new stake in Trupanion during the second quarter valued at approximately $266,000.

Key Stories Impacting Trupanion

Here are the key news stories impacting Trupanion this week:

• Positive Sentiment: Q1 results beat street expectations: Trupanion reported $0.11 EPS vs. ~$0.07 consensus and revenue of $384.05M vs. ~$379.8M, signaling continued top‑line growth and an earnings improvement vs. year‑ago loss. This is the primary near‑term positive catalyst supporting the share price. Zacks: TRUP Q1 Beats
• Neutral Sentiment: Guidance was roughly in line with expectations: management set Q2 revenue at $386M–$392M and FY revenue around $1.6B (in line with consensus). The company did not provide a clear EPS upgrade in the release, which limits upside from the beat. GlobeNewswire: Q1 Results & Guidance
• Negative Sentiment: Analyst/coverage concerns about growth efficiency: coverage noted that Trupanion faces an “earnings test” as growth efficiency issues mount — investors may fear margin pressure or slower unit economics, which can weigh on a stock even after an earnings beat. Investing.com: Growth Efficiency Concerns
• Negative Sentiment: Minor insider selling disclosed: COO John Gallagher sold 431 shares (~$11.8k), a small transaction but sometimes viewed negatively by short‑term traders. The sale does not appear material to ownership but is being noted by the market. InsiderTrades: Insider Sale

Trupanion Company Profile

Trupanion, Inc is a pet medical insurance company that provides comprehensive insurance coverage for cats and dogs. The company’s core offering is a single, customizable medical policy designed to cover veterinary diagnostic tests, surgeries, hospital stays and congenital or hereditary conditions. Trupanion seeks to streamline the claims process by offering direct payment options to participating veterinarians, reducing the need for upfront payments by pet owners.

Founded in 1999 by Darryl Rawlings and headquartered in Seattle, Washington, Trupanion began operations in the early 2000s and has grown its presence through both digital channels and partnerships with veterinary hospitals.